Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.

Young woman standing on scales at home. Weight loss concept
Metsera adds promising early data with amylin analog to its GLP-1 candidate • Source: Shutterstock

More from Strategy

More from Therapy Areas